F. Valduga

1.1k total citations
25 papers, 684 citations indexed

About

F. Valduga is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, F. Valduga has authored 25 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in F. Valduga's work include Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Prostate Cancer Treatment and Research (5 papers). F. Valduga is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Prostate Cancer Treatment and Research (5 papers). F. Valduga collaborates with scholars based in Italy. F. Valduga's co-authors include Enzo Galligioni, Orazio Caffo, Antonella Ferro, Maurizio Amichetti, A. Lucenti, Felice Pasini, Giuseppe Pelosi, Alberto Terzi, Patrick Maisonneuve and Filippo Fraggetta and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

F. Valduga

23 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Valduga Italy	13	319	261	182	107	97	25	684
N. W. Peacock United States	14	237 0.7×	512 2.0×	191 1.0×	127 1.2×	51 0.5×	42	871
Dae Ro Choi South Korea	14	157 0.5×	167 0.6×	85 0.5×	73 0.7×	58 0.6×	43	468
P. Foro Spain	15	340 1.1×	373 1.4×	400 2.2×	222 2.1×	62 0.6×	65	1.0k
S. Bourdin France	15	432 1.4×	326 1.2×	264 1.5×	30 0.3×	90 0.9×	40	887
Carol Marquez United States	13	542 1.7×	188 0.7×	90 0.5×	55 0.5×	43 0.4×	25	1.0k
Eva Brun Sweden	14	354 1.1×	280 1.1×	201 1.1×	109 1.0×	41 0.4×	47	1.1k
Servando Cardona‐Huerta Mexico	12	372 1.2×	499 1.9×	219 1.2×	246 2.3×	26 0.3×	40	946
Alberto Ravaioli Italy	17	343 1.1×	410 1.6×	131 0.7×	227 2.1×	31 0.3×	44	852
G.P.M. ten Velde Netherlands	15	619 1.9×	452 1.7×	100 0.5×	72 0.7×	32 0.3×	31	921
H. S. Rugo United States	19	370 1.2×	925 3.5×	201 1.1×	318 3.0×	50 0.5×	107	1.3k

Countries citing papers authored by F. Valduga

Since Specialization

Citations

This map shows the geographic impact of F. Valduga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Valduga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Valduga more than expected).

Fields of papers citing papers by F. Valduga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Valduga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Valduga. The network helps show where F. Valduga may publish in the future.

Co-authorship network of co-authors of F. Valduga

This figure shows the co-authorship network connecting the top 25 collaborators of F. Valduga. A scholar is included among the top collaborators of F. Valduga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Valduga. F. Valduga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Murgia, Viviana, Antonello Veccia, S. Brugnara, et al.. (2017). Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer. Anti-Cancer Drugs. 28(6). 654–659. 1 indexed citations

2.

Murgia, Viviana, Orazio Caffo, A. Caldara, et al.. (2015). Concurrent chemoradiotherapy (cCTRT) with weekly cisplatin (wCDDP) in locally advanced cervical cancer (LACC) patients (pts): a monoinstitutional experience. Annals of Oncology. 26. vi35–vi35.

3.

Caffo, Orazio, Viviana Murgia, Antonello Veccia, et al.. (2014). Weekly paclitaxel (wPCT) for pretreated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Updated data from a single institution experience in the daily clinical practice.. Journal of Clinical Oncology. 32(15_suppl). e19143–e19143.

4.

Pasini, Felice, Anna Paola Fraccon, Carmen Barile, et al.. (2013). Targeted therapies (TT) in metastatic renal cell carcinoma (mRCC): An Italian survey of 902 pts.. Journal of Clinical Oncology. 31(15_suppl). e15514–e15514. 1 indexed citations

5.

Caffo, Orazio, Giovanni Pappagallo, S. Brugnara, et al.. (2012). Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors. Urology. 79(3). 644–649. 42 indexed citations

6.

Caffo, Orazio, Teodoro Sava, Evi Comploj, et al.. (2008). Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urologic Oncology Seminars and Original Investigations. 28(2). 152–156. 18 indexed citations

7.

Caffo, Orazio, Teodoro Sava, Evi Comploj, et al.. (2008). Docetaxel, with or without estramustine phosphate, as first‐line chemotherapy for hormone‐refractory prostate cancer: results of a multicentre, randomized phase II trial. British Journal of Urology. 102(9). 1080–1085. 28 indexed citations

8.

Galligioni, Enzo, Orazio Caffo, G. Ambrosini, et al.. (2008). Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years’ experience. Annals of Oncology. 20(2). 349–352. 24 indexed citations

9.

Giorgi, Ugo De, Giovanni Rosti, Giorgio Papiani, et al.. (2004). Weekly Gemcitabine, Paclitaxel, Oxaliplatin Combination Chemotherapy in Patients With Cisplatin-Refractory Germ Cell Tumor. American Journal of Clinical Oncology. 27(5). 457–460. 15 indexed citations

10.

Cappuzzo, Federico, Francesca Mazzoni, Alessandra Gennari, et al.. (2004). Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. British Journal of Cancer. 90(1). 31–35. 36 indexed citations

11.

Brandes, Alba A., A. Tosoni, Michele Reni, et al.. (2004). Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group). Journal of Clinical Oncology. 22(14_suppl). 1516–1516. 1 indexed citations

12.

Brandes, Alba A., A. Tosoni, Michele Reni, et al.. (2004). Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group). Journal of Clinical Oncology. 22(14_suppl). 1516–1516. 4 indexed citations

13.

Sorio, Roberto, Germana Tognon, Angela Gambino, et al.. (2004). A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma. Tumori Journal. 90(6). 556–561. 11 indexed citations

14.

Brandes, Alba A., Alicia Tosoni, Umberto Basso, et al.. (2004). Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Journal of Clinical Oncology. 22(23). 4779–4786. 99 indexed citations

15.

Pasini, Felice, Giovanna Verlato, E Durante, et al.. (2003). Persistent excess mortality from lung cancer in patients with stage I non-small-cell lung cancer, disease-free after 5 years. British Journal of Cancer. 88(11). 1666–1668. 14 indexed citations

16.

Caffo, Orazio, Gianni Fellin, F. Valduga, et al.. (2003). Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. International Journal of Radiation Oncology*Biology*Physics. 57(5). 1310–1316. 39 indexed citations

17.

Caffo, Orazio, Maurizio Amichetti, Antonella Ferro, et al.. (2003). Pain and Quality of Life after Surgery for Breast Cancer. Breast Cancer Research and Treatment. 80(1). 39–48. 146 indexed citations

18.

Pasini, Felice, Giuseppe Pelosi, F. Valduga, et al.. (2002). Late events and clinical prognostic factors in stage I non small cell lung cancer. Lung Cancer. 37(2). 171–177. 19 indexed citations

19.

Amichetti, Maurizio, Orazio Caffo, S. Brugnara, F. Valduga, & Enzo Galligioni. (2001). Pain after quadrantectomy and radiotherapy (QUART) for early-stage breast cancer (BC): incidence, characteristics and influence on quality of life (QL). Results from a retrospective study. International Journal of Radiation Oncology*Biology*Physics. 51(3). 365–365. 1 indexed citations

20.

Pelosi, Giuseppe, Filippo Fraggetta, Felice Pasini, et al.. (2001). Immunoreactivity for Thyroid Transcription Factor-1 in Stage I Non–Small Cell Carcinomas of the Lung. The American Journal of Surgical Pathology. 25(3). 363–372. 158 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact